Background: Ki67LI is a relevant marker EBC. The 2009 St Gallen Consensus considered Ki67LI as an important parameter for the addition of chemotherapy to endocrine therapy in hormonereceptor-positive EBC, suggesting three cutoffs: low <15%, intermediate 15-30% and high >30%. Our study aimed to evaluate if these cutoffs can be used in different subgroups of EBC, or if to apply different cutoffs in distinct biological setting. Methods: Ki67LI 1 was identified by immunohistochemical staining in 3802 EBC pts treated from 1995 to 2008. Median age was 61. The relationship with clinic-pathological parameters and the prognostic significance of KI67LI was investigated in all EBCs and in subgroups of ER+ cases based on homogeneous grading (656 G1, 1535 G2, 1113 G3). Results: Median Ki67LI values were 22% in all cases and 10, 20 and 36% in ER+ G1, G2 and G3 respectively. High Ki67LI was significantly (p<0.001) associated with younger age, ductal type, greater size, positive N, poor G, absent or low ER /PR, positive HER-2, triple negative subtypes, larger use of chemo±hormonotherapy. At median f-up of 51 months DFS and OS were 84 and 85% respectively in high, 89 and 90% in intermediate, 92 and 94% respectively in low Ki67LI group (p <0.001). There were 456 relapses (12%): 207 (5.4%) in high, 136 (3.6%) in intermediate and 113 (3%) in low Ki67LI group. Using median ki67LI value for different homogenous ER+ grading groups (ER+GG) we stratified these populations in low and high risk. The results are shown in the table. Conclusions: Ki67 LI confirms to be a significant prognostic biomarker for DFS and OS in EBC, associated with other clinical-pathological characteristics. Cutoffs are different into ER+GG. They can cathegorize at least two biological entities in every grading group providing additional prognostic information in planning therapies and outcome prediction.
Role of Ki67 labeling index (LI) in subdividing homogeneous ER-positive grading groups of early breast cancer (EBC) in distinct biologic entities
Eccher, Claudio;Berloffa, Flavio;
2011-01-01
Abstract
Background: Ki67LI is a relevant marker EBC. The 2009 St Gallen Consensus considered Ki67LI as an important parameter for the addition of chemotherapy to endocrine therapy in hormonereceptor-positive EBC, suggesting three cutoffs: low <15%, intermediate 15-30% and high >30%. Our study aimed to evaluate if these cutoffs can be used in different subgroups of EBC, or if to apply different cutoffs in distinct biological setting. Methods: Ki67LI 1 was identified by immunohistochemical staining in 3802 EBC pts treated from 1995 to 2008. Median age was 61. The relationship with clinic-pathological parameters and the prognostic significance of KI67LI was investigated in all EBCs and in subgroups of ER+ cases based on homogeneous grading (656 G1, 1535 G2, 1113 G3). Results: Median Ki67LI values were 22% in all cases and 10, 20 and 36% in ER+ G1, G2 and G3 respectively. High Ki67LI was significantly (p<0.001) associated with younger age, ductal type, greater size, positive N, poor G, absent or low ER /PR, positive HER-2, triple negative subtypes, larger use of chemo±hormonotherapy. At median f-up of 51 months DFS and OS were 84 and 85% respectively in high, 89 and 90% in intermediate, 92 and 94% respectively in low Ki67LI group (p <0.001). There were 456 relapses (12%): 207 (5.4%) in high, 136 (3.6%) in intermediate and 113 (3%) in low Ki67LI group. Using median ki67LI value for different homogenous ER+ grading groups (ER+GG) we stratified these populations in low and high risk. The results are shown in the table. Conclusions: Ki67 LI confirms to be a significant prognostic biomarker for DFS and OS in EBC, associated with other clinical-pathological characteristics. Cutoffs are different into ER+GG. They can cathegorize at least two biological entities in every grading group providing additional prognostic information in planning therapies and outcome prediction.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
